SATuRN and BioAfrica open access reports:

Here we provide you with sections from our open access annual reports, which are directed at public health practitioners, policies makers, doctors, researchers and the general public.

The objective of these reports is to present the key aspects of our work in an accessible, summarized format. The majority of the work presented has been published in peer-reviewed publications and can be seen in the publications section of bioafrica.net.


Report Latest Reports

In adult patients failing a second-line protease inhibitor regimen lopinavir concentration measurement in plasma or hair are helpful to exclude patients with poor adherence from unnecessary resistance testing

Authors: van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G.

Background:

South African patients receiving a regimen of LPV/r, didanosine and zidovudine as a second regimen have a high prevalence of virological failure (30-40%). This could be due the poor tolerability of the regimen. However problems with adherence are often not disclosed.

Objective:

Therefore objective measures of drug exposure such as plasma concentration (recent drug use) or hair concentration (longer term drug use) could be helpful in identifying those patients with failure despite good adherence who would need resistance testing. In a study of patients failing this second-line regimen in 2009 conducted in two public healthcare sites, only 2 of 93 patients on this regimen had protease inhibitor resistance.

Results:

A high lopinavir plasma or hair concentration had a negative predictive value of 86% and 89%, for virological failure and the use of both plasma and hair concentrations could detect all patients with inadequate drug exposure and who did not have resistance while having virological failure of the regimen.

Conclusion:

We therefore propose that lopinavir hair and or plasma measurement should form part of the work-up of patients failing a second-line boosted protease inhibitor regimen to exclude patients with inadequate adherence from genotypic antiretroviral resistance testing.

SATuRN output, All reports...
SATuRN 2012 report - 2nd Nurses and Health Care Workers Drug Resistance Training for the scale-up of resistance testing in the Free State Province, South Africa
SATuRN 2012 report - SATuRN's Featured Partner: New TB centre at the London School of Hygiene and Tropical Medicine
SATuRN 2012 report - SATuRN's Featured Partner: Division of Medical Virology, Stellenbosh University
SATuRN output, All reports...


Page design updated by Tulio de Oliveira, 2011